A screening protocol for repurposed drugs that rescue frataxin-dependent defects in FRDA fibroblasts resulted in the identification of dimethyl fumarate (DMF) (Sahdeo et al., 2014), which dose-dependently increases frataxin in FRDA patient lymphoblasts. This evidence concerns the gene FXN and Friedreich ataxia.